This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Arteriovenous Malformation of Precerebral Vessels뇌의 동맥앞부분혈관의 동정맥기형 (뇌동맥전부혈관 동정맥기형)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q28.0 (arteriovenous malformation of precerebral vessels) | Special Copayment Reduction: V191 (special copayment reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsCongenital precerebral arteriovenous malformation, cervical arteriovenous malformation, precerebral AVM, congenital carotid/vertebral arteriovenous malformation, congenital precerebral arteriovenous aneurysm (nonruptured)
C. Adult onsetAlthough the lesion is congenital, symptom onset is common in young and middle adulthood (20s–50s), presenting as hemorrhage, neurological deficits or an incidental finding.
1. HistoryIt began to be described in autopsy reports from the late 19th century, and antemortem diagnosis became possible after the introduction of cerebral angiography.
2. CausesA congenital vascular malformation arising from abnormal embryonic vasculogenesis, originating in precerebral vessels such as the internal carotid and vertebral arteries.
3. GeneticsMost cases are sporadic, but some are associated with HHT (hereditary hemorrhagic telangiectasia)-related ENG and ACVRL1 mutations or RASA1 variants.
4. General epidemiologyThe overall prevalence of brain and precerebral AVMs is about 10–18 per 100,000 population; precerebral locations account for a minority of all intracranial AVMs.
5. PathophysiologyA nidus forms in which arteries connect directly to veins without a capillary network, so high-pressure blood flow enters the venous system directly.
6. SymptomsVarious neurovascular symptoms occur, including headache, pulsatile tinnitus, cervical bruit, transient ischemic attack, ischemic stroke and hemorrhage.
7. SignsA continuous bruit on auscultation of the cervical vessels, a thrill on palpation and signs of focal neurological deficit may be present.
8. ScreeningCervical Doppler ultrasound is the first-line screen; if abnormal flow is found, further evaluation is done with CTA or MRA.
9. DiagnosisDSA is the standard for definitive diagnosis, and MRI/MRA and CTA are used for noninvasive evaluation. Spetzler-Martin grading is applied.
10. TreatmentEndovascular embolization, stereotactic radiosurgery (Gamma Knife, CyberKnife), resection via craniotomy or combined treatment is chosen according to lesion characteristics.
11. PrognosisThe obliteration rate after treatment varies with lesion size and vascular architecture; if untreated, the annual risk of hemorrhage is about 2–4%.
12. PreventionBecause the lesion is congenital, primary prevention is not possible, but management of hemorrhage risk factors (blood pressure control, cautious use of anticoagulants) is important.
13. ReferencesBerman MF et al. The epidemiology of brain arteriovenous malformations … and 9 other papers

1. History

The first systematic descriptions of congenital arteriovenous malformations arising in the precerebral vessels — that is, the internal carotid artery, vertebral artery, basilar artery and others — were made in the mid-to-late 19th century. The starting point was when German pathologists began to discover and record abnormal vascular connections in the cervical vessels at autopsy. At the time, however, there was no means of antemortem diagnosis, so most cases were diagnosed only after death.

In 1927, Antonio Egas Moniz developed cerebral angiography, bringing about a revolutionary shift that made antemortem diagnosis of vascular malformations possible. This led to studies that confirmed arteriovenous malformations of the precerebral vessels by imaging in living patients and followed their clinical course. In the 1950s–1960s, as pioneering neurosurgeons such as Walter Dandy and Charles Drake advanced the surgical treatment of cerebral aneurysms and vascular malformations, surgical approaches to precerebral AVM also gradually became systematized.

In the 1970s–1980s, the introduction of CT and MRI made noninvasive imaging diagnosis possible, and the anatomical classification of vascular malformations became more refined. In 1986, Spetzler and Martin published a grading system for brain AVMs (Spetzler-Martin grading system), contributing to the standardization of surgical risk prediction; however, this system applies mainly to intracranial AVMs, and modified criteria are applied to AVMs of the precerebral vessels.

Since the 1990s, advances in endovascular embolization and stereotactic radiosurgery (SRS) have greatly broadened the treatment options for precerebral AVMs in anatomically complex locations. As radiosurgery devices such as the Gamma Knife, linear accelerator (LINAC) and CyberKnife were introduced into clinical practice, noninvasive treatment became possible even for lesions difficult to approach surgically.

Since the 2010s, advances in genomic research have begun to identify gene variants involved in AVM formation, and advances in endovascular techniques (liquid embolic agents, flow-diverting devices, etc.) have further improved treatment outcomes. Evidence on the optimal treatment strategy for unruptured AVMs continues to accumulate through international multicenter studies (such as the ARUBA trial).


2. Causes

Arteriovenous malformation of precerebral vessels, classified as Q28.0, is a congenital vascular lesion arising from abnormal vasculogenesis and angiogenesis during embryonic development. The core pathogenesis is failure of differentiation of the primitive vascular network into arteries, capillaries and veins during weeks 4–8 of early gestation, with formation of abnormal direct connections (nidus) between arteries and veins.

In normal development, formation of the capillary network connecting arteries and veins requires the precise coordination of various molecular pathways, including vascular endothelial growth factor (VEGF), Notch signaling and TGF-β signaling. If a particular signaling molecule or receptor malfunctions in this process, direct arteriovenous connections may form instead of capillaries. In particular, NOTCH4 hyperactivation, abnormalities of the EphrinB2/EphB4 axis and disruption of the BMP (bone morphogenetic protein) signaling pathway are being studied as linked to failure of arteriovenous differentiation.

When an AVM forms in the internal carotid system or vertebrobasilar system corresponding to the precerebral vessels, the lesion may extend intracranially or be confined to the neck. It resembles a carotid-cavernous fistula, but a congenital AVM is distinguished by having a nidus without capillaries. Structural abnormalities of the vessel wall — absence of the elastic lamina and lack of medial smooth muscle — are also present and increase the risk of rupture.


3. Genetics

The great majority of arteriovenous malformations of precerebral vessels occur sporadically and do not follow a clear pattern of inheritance. In some patients, however, an association with specific genetic syndromes has been confirmed.

Hereditary Hemorrhagic Telangiectasia (HHT) is the genetic disorder most closely associated with AVM. HHT type 1 is caused by autosomal dominant mutations in the ENG (endoglin) gene on chromosome 9q34, and HHT type 2 by mutations in the ACVRL1 (ALK1) gene on 12q13. These two proteins play key roles in maintaining vascular endothelial cell homeostasis in the TGF-β signaling pathway, and loss of function leads to the formation of multiple abnormal vascular connections. Brain AVMs are observed in about 5–20% of HHT patients.

Mutations in the RASA1 gene (12q21.1) are associated with capillary malformation–arteriovenous fistula–Parkes Weber syndrome (capillary malformation–arteriovenous malformation, CM-AVM) and are also related to some precerebral vessel AVMs. RASA1 encodes a GTPase-activating protein that regulates the RAS-MAPK signaling pathway, and mutations in this gene promote abnormal vascular growth.

A somatic mutation hypothesis has also been proposed. Studies have found somatic gain-of-function mutations in RAS-MAPK pathway genes such as KRAS, MAP2K1 and BRAF in sporadic AVM tissue, suggesting that AVMs may be formed by two genetic mutations (two-hit model). Genetic testing is selectively recommended when a genetic syndrome such as HHT is suspected.


4. General epidemiology

The overall prevalence of arteriovenous malformations of the brain and precerebral vessels is estimated at about 10–18 per 100,000 population, with an annual detection rate of about 1–1.5 per 100,000 population. Q28.0 lesions confined to the precerebral vessels account for a minority of all cranial and juxtacranial AVMs, and accurate prevalence data are limited.

Overall, the sex distribution is similar or tends to be slightly more common in men (male:female = about 1.1–1.2:1). By age, despite being a congenital lesion, the median age at first diagnosis on symptom onset is most often in the 30s–40s. This is because relatively small lesions or those in a compensated hemodynamic state may produce no symptoms for a long time, with symptoms appearing as the lesion grows or hemodynamic changes accumulate.

Geographically, there are no data showing a higher incidence in particular regions, but for HHT-related AVMs, related lesions are found at higher frequency in regions where HHT is relatively common (e.g., parts of France). The proportion of unruptured AVMs found incidentally is increasing with greater use of MRI, and accordingly it has become more important to consider the natural history of asymptomatic AVMs in treatment decisions.


5. Pathophysiology

The core structure of a precerebral AVM consists of three elements: the nidus, the feeding arteries and the draining veins. The nidus is an abnormal tangle of vessels in which arteries and veins are intertwined without a capillary network; its vessel walls are thin and irregular, with incomplete elastic lamina and smooth muscle.

Because there is no normal capillary resistance, high-pressure arterial flow enters the venous system directly, and the following pathophysiological changes occur in the process. First, flow velocity and volume in the feeding arteries increase greatly, and over time the feeding arteries become dilated and tortuous (ectasia). Second, as high-pressure flow passing through the nidus is transmitted to the draining veins, venous hypertension develops, which can cause venous arterialization, varix formation and venous thrombosis. Third, steal ischemia occurs in normal brain tissue around the nidus, causing focal neurological symptoms.

The risk of rupture is related to focal high-pressure zones within the nidus, intranidal aneurysms, and increased venous hypertension due to occlusion or stenosis of the draining veins. At the molecular level, oxidative stress, inflammatory cytokines (IL-1β, TNF-α) and overexpression of MMPs (matrix metalloproteinases) have been reported to contribute to weakening of the nidal vessel walls.


6. Symptoms

The clinical symptoms of precerebral AVM vary widely depending on lesion size, flow volume, presence of hemorrhage and degree of steal ischemia.

Hemorrhage-related symptoms are the most serious, presenting with sudden severe headache (thunderclap headache), altered consciousness, nausea and vomiting, and focal neurological deficits. Rupture of a precerebral vessel AVM can cause subarachnoid hemorrhage (SAH), intracranial hemorrhage (ICH) or a cervical hematoma.

Ischemia-related symptoms may include transient ischemic attack (TIA) and symptoms of ischemic stroke (hemiparesis, aphasia, visual field defects, etc.). This is because the steal effect of the AVM reduces blood flow to the surrounding brain tissue, or emboli associated with the AVM travel distally.

Symptoms related to the cervical vessels may include pulsatile tinnitus, awareness of a cervical bruit, and head and neck pain. In large precerebral AVMs, compression of cranial nerves may cause facial palsy, dysphagia and voice changes. Epileptic seizures are rarer than in intracranial AVMs but may occur when the lesion extends to the skull base.


7. Signs

Signs characteristic of precerebral AVM can be identified on physical examination.

The most characteristic finding on auscultation of the cervical vessels is a continuous bruit, which may be heard over the internal carotid or vertebral artery. The bruit peaks in systole and persists into diastole, and its intensity may change with head rotation or compression of the carotid artery on the side of the lesion. In some cases a bruit may also be heard on cranial auscultation (including the orbital region).

On palpation, a thrill may be felt over the cervical vessels, reflecting turbulent flow. Neurological examination may reveal dysfunction of cranial nerves adjacent to the lesion — ipsilateral facial hypoesthesia, decreased hearing, nystagmus and ataxia. Funduscopic examination may show retinal vascular abnormalities (venous congestion, vascular dilation).

After hemorrhage, signs of meningeal irritation (neck stiffness, Kernig sign, Brudzinski sign), decreased consciousness and focal neurological deficits appear, requiring emergency evaluation equivalent to that for subarachnoid or intracranial hemorrhage. Changes in vital signs such as elevated blood pressure and tachycardia or bradycardia (with raised intracranial pressure) may also accompany this.


8. Screening

In screening for precerebral AVM, the initial approach depends on the clinical symptoms and location. When a cervical vascular abnormality is suspected, carotid duplex ultrasonography is useful as a first-line screening test. If abnormal flow waveforms — flow acceleration, venous arterialization, abnormal flow direction — are found, AVM is suspected and further tests are performed.

When headache or neurological symptoms develop acutely, non-contrast brain CT is performed first to rapidly assess for hemorrhage. If hemorrhage is found on brain CT, CTA is added immediately to evaluate for a vascular malformation. In the non-acute setting, brain MRI is used for screening, and flow voids and vascular dilation on T2-weighted images suggest an AVM.

In patients with suspected HHT (headache with a family history, recurrent epistaxis, cutaneous telangiectasia, etc.), brain MRI screening is strongly recommended after the HHT diagnostic criteria (Curaçao criteria) are checked. If screening is positive, diagnostic angiography is performed.


9. Diagnosis

Digital subtraction angiography (DSA) is the gold standard for diagnosis of precerebral AVM. It provides the most accurate dynamic flow information — identification of feeding arteries, nidus architecture, draining vein pathways and flow transit time — and is essential for treatment planning. Pan-cerebral angiography including bilateral internal carotid and vertebral artery injections is required.

CT angiography (CTA) allows rapid assessment of the three-dimensional anatomical relationships of the nidus, feeding arteries and draining veins through 3D reconstruction, making it useful in emergencies. Brain MRI and MR angiography (MRA) are used to noninvasively assess the soft tissue, the relationship with surrounding brain tissue and the morphological features of the vascular malformation. Functional MRI (fMRI) is used preoperatively to determine the relationship between the lesion and functional cortex.

The Spetzler-Martin grading system (grades I–V by size, proximity to eloquent brain areas and venous drainage pattern) is used for risk classification of the lesion, and adjustment may be needed to reflect the particularities of the precerebral location. Associated vascular abnormalities (feeding artery aneurysms, intranidal aneurysms) increase the risk of rupture and must be carefully evaluated on DSA.


10. Treatment

The goals of treatment for precerebral AVM are prevention of hemorrhage and preservation of neurological function, and the choice of treatment is made on a multidisciplinary basis according to lesion size, location, flow characteristics, patient age and general condition.

Endovascular embolization is a method in which a catheter is advanced to the feeding artery and a liquid embolic agent (Onyx, NBCA, etc.) or coils are injected into the nidus to block blood flow. Because it often cannot achieve complete obliteration on its own, it is commonly used as 'preparatory embolization' to reduce lesion size before surgery or radiosurgery. Embolization of precerebral AVMs located in the neck may be more accessible than that of intracranial AVMs.

Stereotactic radiosurgery (SRS) delivers focused high-dose radiation to the lesion using the Gamma Knife or a linear accelerator. Radiation stimulates proliferation of the endothelial cells of the vessel wall, gradually obliterating the nidus; complete obliteration usually takes 2–4 years. It is effective for lesions less than 3 cm in size and is preferred for lesions in locations where surgical resection is risky.

Surgical resection is a treatment that offers the prospect of cure for low-grade (Spetzler-Martin I–II) AVMs in accessible locations. Depending on the precerebral location, the lesion is resected via craniotomy or a cervical approach. For high-grade (IV–V) AVMs or those in difficult-to-access regions, the risk is high and careful patient selection is required. Combined treatment (embolization + SRS, or embolization + surgery) is sometimes more effective than single-modality treatment.


11. Prognosis

In the natural history of untreated precerebral AVM, the annual risk of hemorrhage is reported to be about 2–4%, similar to brain AVM. After a first hemorrhage, the risk of rebleeding rises to about 6–18% within the first year and then gradually returns to baseline. Mortality from a first hemorrhage is estimated at about 10–15%, and the rate of permanent neurological disability at about 20–30%.

Prognosis after treatment varies with the treatment method and lesion characteristics. When complete obliteration is achieved, the subsequent risk of hemorrhage approaches zero. The complete obliteration rate after radiosurgery is about 60–80% at 2–3 years of follow-up, and the risk of hemorrhage persists during the period before obliteration is confirmed. Complete obliteration after surgical resection is confirmed by DSA, and after successful resection the neurological prognosis depends largely on the preoperative functional status.

Regarding intervention vs. observation for unruptured AVMs, the results of the ARUBA study (A Randomized Trial of Unruptured Brain AVMs) favored observation, but debate over this continues, so multidisciplinary review for each individual patient is essential.


12. Prevention

There is currently no way to prevent the occurrence of precerebral AVM, a congenital vascular malformation. Prevention strategies therefore focus mainly on secondary prevention, that is, preventing hemorrhage and minimizing complications in patients already diagnosed with AVM.

Blood pressure control is the most important reversible risk factor for reducing the risk of rupture. Maintaining normal blood pressure (< 130/80 mmHg) can reduce the pressure on the vessel walls within the nidus and lower the risk of hemorrhage. Hypertension significantly increases the annual risk of hemorrhage in AVM patients, so aggressive blood pressure control is recommended. Anticoagulants and antiplatelet agents should be used cautiously once an AVM has been diagnosed, and even when truly necessary, their benefit must be carefully weighed against the risk of hemorrhage.

In families of HHT patients, early detection of AVM through genetic testing and brain MRI screening is important. Because pregnancy increases the hemodynamic load and may raise the risk of AVM rupture, AVM patients planning a pregnancy should carefully decide on treatment before pregnancy. Patients are educated to avoid strenuous Valsalva maneuvers and activities that cause sudden rises in blood pressure. It is important to monitor changes in lesion size and hemodynamics through a follow-up plan (regular MRI, DSA) and to determine the timing of treatment.


13. References

  1. Berman MF, Sciacca RR, Pile-Spellman J, et al. The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000;47(2):389-396. DOI: 10.1097/00006123-200008000-00023. PMID: 10942013.

  2. Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917):614-621. DOI: 10.1016/S0140-6736(13)62302-8. PMID: 24461883.

  3. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65(4):476-483. DOI: 10.3171/jns.1986.65.4.0476. PMID: 3760956.

  4. Kim H, Su H, Weinsheimer S, et al. Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm. Acta Neurochir Suppl. 2011;111:83-92. DOI: 10.1007/978-3-7091-0693-8_14. PMID: 21725740.

  5. Willemse RB, Mager JJ, Westermann CJ, et al. Bleeding risk of cerebrovascular malformations in hereditary hemorrhagic telangiectasia. J Neurosurg. 2000;92(5):779-784. DOI: 10.3171/jns.2000.92.5.0779. PMID: 10794290.

  6. Stapf C, Mast H, Sciacca RR, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006;66(9):1350-1355. DOI: 10.1212/01.wnl.0000210524.68507.87. PMID: 16682666.

  7. Cognard C, Gobin YP, Pierot L, et al. Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage. Radiology. 1995;194(3):671-680. DOI: 10.1148/radiology.194.3.7862961. PMID: 7862961.

  8. Starke RM, Yen CP, Ding D, Sheehan JP. A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations. J Neurosurg. 2013;119(4):981-987. DOI: 10.3171/2013.5.JNS122296. PMID: 23829840.

  9. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg. 2013;118(2):437-443. DOI: 10.3171/2012.10.JNS121280. PMID: 23140129.

  10. van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011-2019. DOI: 10.1001/jama.2011.1632. PMID: 22068990.